Milestone Scientific Announces Addition of Ausra Burniene as Senior Sales & Marketing Consultant

LIVINGSTON, NJ -- (Marketwired) -- 10/20/16 -- Milestone Scientific, Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced the expansion of the sales and marketing team with the appointment of Ausra Burniene as Senior Sales & Marketing Consultant.

Ms. Burniene brings over 17 years of international and medical device industry experience. Ms. Burniene managed the development and launch of several key new products throughout Europe and internationally. Prior to joining Milestone, Ms. Burniene was Regional Sales Manager, Eastern and Northern Europe, for Micrel Medical Devices, where she increased turnover of ambulatory infusion pumps and disposables three times over three years. Previously, Ms. Burniene served as Distributor Manager of MOOG Medical Devices Group, USA where she oversaw sales of medical devices and a network of over 80 medical distributors in 20 countries across Europe, the Middle East, Africa and Asia. Ms. Burniene has an MBA and Bachelors in Business Management from Vilnius University in Lithuania.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are pleased to welcome Ms. Burniene to the team. She brings extensive experience and relationships that will aid in accelerating our efforts to enter into domestic and international distribution agreements in advance of FDA marketing clearance of our epidural computer controlled injection system."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2015. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Tel: 212-671-1020

Source: Milestone Scientific, Inc.